Eton Pharmaceuticals Inc. logo

Eton Pharmaceuticals Inc. (ETON)

Market Closed
17 Jul, 20:00
NASDAQ (NMS) NASDAQ (NMS)
$
42. 32
+5.13
+13.794%
$
1.03B Market Cap
- P/E Ratio
- Div Yield
1.28M Volume
0.26 Eps
$ 37.19
Previous Close
Add Transaction
Day Range
37 42.65
Year Range
13.78 42.65
Want to track ETON and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

ETON closed today higher at $42.32, an increase of 13.794% from yesterday's close, completing a monthly increase of 39.4858% or $11.98. Over the past 12 months, ETON stock gained 150.7109%.
ETON is not paying dividends to its shareholders.
The last earnings report, released on May 07, 2026, missed the consensus estimates by -0.28%. On average, the company has fell short of earnings expectations by -0.1767%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on one exchange.

ETON Chart

People also search for

Nurix Therapeutics Inc.
$ 23.12
+0.2167%
Urogen Pharma Ltd.
$ 40.23
+0.575%
GH Research plc
$ 28.71
-1.4418%
Eventide Healthcare & Life Sciences Fund Class A Shares
$ 55.12
+1.9419%
Maze Therapeutics Inc.
$ 28.12
+3.5156%
Eton Pharmaceuticals, Inc. (ETON) Q1 2026 Earnings Call Transcript

Eton Pharmaceuticals, Inc. (ETON) Q1 2026 Earnings Call Transcript

Eton Pharmaceuticals, Inc. (ETON) Q1 2026 Earnings Call Transcript

Seekingalpha | 2 months ago
Eton Pharmaceuticals Q1 Earnings Call Highlights

Eton Pharmaceuticals Q1 Earnings Call Highlights

Eton Pharmaceuticals NASDAQ: ETON raised its 2026 revenue outlook after reporting record first-quarter product sales and highlighting early progress from two recent product launches, DESMODA and HEMANGEOL.

Marketbeat | 2 months ago
Eton Pharmaceuticals, Inc. (ETON) Misses Q1 Earnings Estimates

Eton Pharmaceuticals, Inc. (ETON) Misses Q1 Earnings Estimates

Eton Pharmaceuticals, Inc. (ETON) came out with quarterly earnings of $0.05 per share, missing the Zacks Consensus Estimate of $0.1 per share. This compares to earnings of $0.07 per share a year ago.

Zacks | 2 months ago

Eton Pharmaceuticals Inc. Investors

Name Quantity Cost Value Profit ($) Gain (%)
Joseph Castro
Joseph Castro Nuveen LLC
57,950 $825,787.26 $2.21M $1.39M 168.08%
Li Peng
Li Peng China Universal Asset Management Co. Ltd.
4,759 $83,497.22 $182,555.24 $99,058.02 118.64%
Ana-Maria Ignat
Ana-Maria Ignat Covestor Ltd
28 $691.04 $1,079.4 $388.36 56.2%
JMP
James M. Perkins Quantum Private Wealth LLC
11,500 $30,130 $431,250 $401,120 1,331.3%
IC
Irene Chou Panoramic Capital LLC
185,000 $4.57M $7.21M $2.65M 57.96%

Eton Pharmaceuticals Inc. (ETON) FAQ

What is the stock price today?

The current price is $42.32.

On which exchange is it traded?

Eton Pharmaceuticals Inc. is listed on NASDAQ (NMS).

What is its stock symbol?

The ticker symbol is ETON.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 1.03B.

Has Eton Pharmaceuticals Inc. ever had a stock split?

No, there has never been a stock split.

Eton Pharmaceuticals Inc. Profile

Biotechnology Industry
Healthcare Sector
Sean E. Brynjelsen CEO
NASDAQ (NMS) Exchange
29772L108 CUSIP
US Country
44 Employees
- Last Dividend
- Last Split
13 Nov 2018 IPO Date

Overview

Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company with a focused mission of developing, acquiring, and bringing to market pharmaceutical products aimed at treating rare diseases. Founded in 2017 and headquartered in Deer Park, Illinois, Eton Pharmaceuticals identifies unmet medical needs in the rare disease space and addresses them through innovative treatment solutions. The company's strategy underscores its commitment to improving the lives of patients, especially children suffering from complex and rare conditions that require specialized therapeutic interventions.

Products and Services

  • ALKINDI SPRINKLE

    ALKINDI SPRINKLE stands out as a unique replacement therapy specifically formulated for managing adrenocortical insufficiency in children under the age of 17. This essential treatment offers a lifeline for young patients dealing with this rare condition, ensuring they receive the necessary hormonal support for everyday health and well-being.

  • Carglumic Acid

    Carglumic Acid is approved for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency. This product plays a critical role in managing a condition that can lead to dangerous levels of ammonia in the blood, presenting a vital solution for affected individuals.

  • Betaine Anhydrous

    This therapeutic option is targeted at treating homocystinuria, a rare disorder affecting the metabolism of the amino acid methionine. Betaine Anhydrous helps reduce harmful levels of homocysteine in the blood, thereby mitigating potential complications and improving the quality of life for those with homocystinuria.

  • Nitisinone

    Nitisinone is prescribed for the treatment of hereditary tyrosinemia type 1, a genetic disorder that can lead to severe liver and kidney problems. By using Nitisinone, patients can manage the effects of the condition, preventing significant organ damage and enhancing longevity and life quality.

  • Zeneo Hydrocortisone Autoinjector

    As a novel solution for the emergency treatment of adrenal crisis, the Zeneo hydrocortisone autoinjector is a significant advancement in the care of patients with chronic adrenal insufficiency. This device empowers patients and caregivers by providing a quick, effective, and easy-to-use means of administering life-saving medication during a crisis.

Contact Information

Address: 21925 W. Field Parkway
Phone: 847 787 7361